In cattle feedlots where calcareous phosphorus deficiency drives bone chewing and type C botulism outbreaks, the inactivated Clostridium botulinum type C toxoid API is formulated as an aluminium hydroxide-adsorbed subcutaneous suspension. Bulk toxoid received at pH 6.8–7.2 and 2–8°C is standardised by Lf titre and residual free formaldehyde; the chromotropic acid method is used to confirm free formaldehyde below 0.02% w/v before blending. In final formulations, the API is incorporated at 20–45% v/v after potency adjustment rather than fixed volume; the dose target is 2 mL containing 1.0–2.0 IU type C toxoid and 1.25–2.5 mg aluminium as aluminium hydroxide. Compliance is anchored to 9 CFR § 113.100 for inactivated bacterial products, sterility by USP <71>, endotoxin by Ph. Eur. 2.6.14 at ≤20 EU/mL, and cleanroom handling under ISO 14644-1:2015 Class 8. Downstream processing uses a closed 316L stainless steel jacketed vessel; the aluminium hydroxide gel is added at 2% w/v under 75–120 rpm low-shear impeller for 60–90 min at 4–8°C, followed by pH adjustment to 6.5–6.9 with 0.1 M hydrochloric acid or sodium hydroxide. Filling into 100 mL or 250 mL polypropylene multidose vials with bromobutyl stoppers is performed by rotary piston pumps with 0.22 µm vent filters. Field-run observations on commercial fill lines indicate that aluminium gel sedimentation in the dead volume between the holding tank and filling needles causes subpotency in the first 5–10 vials if recirculation is below 50 rpm; the fill-line dead volume is therefore held below 0.5 L and slow recirculation is maintained during the entire campaign. Tablet, capsule, powder, granule, and premix presentations are not used for this antigen in cattle because the toxoid is acid-denatured below pH 3.0 and proteolytically degraded in ruminal and abomasal fluid; no regulatory potency standard exists for oral botulinum toxoid presentations.

What Drives the Adsorption Time Window in Ovine and Caprine C/D Multivalent Suspensions?

Ovine and caprine flocks on extensively grazed, phosphorus-poor soils are vaccinated with a blend of type C and D toxoid formulated as a 2 mL subcutaneous injection. The adsorption time onto aluminium hydroxide gel in vessels above 500 L is the main production bottleneck; equilibrium at 4°C requires 18–24 h, and filling before 12 h produces antigen desorption and a supernatant haze that fails visual inspection. Bulk toxoid inclusion in ovine formulations is not listed in public monographs; published data for this specific configuration is limited. Campaign records from multivalent clostridial vaccines indicate a working inclusion of 20–45% v/v after potency standardisation, with final aluminium content not exceeding 2.0 mg per 2 mL dose. The downstream process operates in a 1,000 L jacketed 316L vessel with a bottom-mounted magnetic-drive impeller; the sterile 2.5% w/v aluminium hydroxide slurry is introduced at ≤1 L/min to prevent gel layering. Terminal finished product types include 100 mL and 250 mL HDPE vials and, in smallholder markets, 50 mL rubber-stoppered Type I glass vials. Compliance relies on 9 CFR § 113.100, Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.7 where mycoplasma screening is required for serum-source components, and the WOAH Terrestrial Manual chapter on botulism for mouse toxin neutralisation potency. The formulation is not compatible with citrate or phosphate buffers above 10 mM because higher concentrations precipitate aluminium phosphate and shift the gel surface charge; 10 mM acetate buffer at pH 6.3 is used. Tablets, capsules, and oral premixes are absent from licensed ovine type C products because ruminal pH degradation and the absence of an oral potency test prevent dose assurance.

Mink and Captive Mustelid Subcutaneous Suspension Constraints

Mink and captive ferrets experiencing type C botulism require a 1 mL subcutaneous dose with lower aluminium residuals than ruminant doses; injection-site granulomas occur in mustelids when aluminium exceeds 0.5 mg per dose. The toxoid API is diluted to 10–20% v/v in sterile isotonic saline containing 0.5% w/v phenol, targeting 1.0 IU type C toxoid per 1 mL dose and aluminium not exceeding 0.3 mg Al³⁺ from aluminium phosphate or aluminium hydroxide. Some lines omit aluminium adjuvant completely and rely on a two-dose primary series at 3-week intervals, but published data for this specific configuration is limited. Downstream production uses single-use bag mixing with peristaltic recirculation at 20 rpm because high-shear agitation releases weakly adsorbed toxoid into the free phase. Filling occurs on a compact rotary piston line into 10 mL or 50 mL Type I glass vials with chlorobutyl stoppers; terminal finished product types are 50 mL multidose vials and 1 mL single-dose syringes. Compliance is anchored to Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for endotoxin ≤10 EU/mL, and 9 CFR § 113.100 for US export batches. The final blend is held for 4–6 h at 4°C before filling; holds beyond 12 h are rejected because free toxoid release measured by capture ELISA exceeds the internal release limit. Tablet, capsule, powder, granule, and premix forms are not applied in mustelid vaccination; oral bait delivery has been investigated experimentally but no commercial potency test exists.

Where waterfowl, pheasant, and broiler breeder flocks experience type C botulism, the toxoid API is formulated as a water-in-oil emulsion rather than an aluminium-heavy ruminant suspension. The aqueous phase contains the type C toxoid at 15–25% v/v after potency adjustment, with 0.5% w/v phenol or 0.01% w/v thimerosal; the oil phase is light mineral oil with mannide monooleate surfactant, and the final aqueous-to-oil ratio is 30:70. Downstream emulsification uses an inline rotor-stator at 6,000–10,000 rpm for 5–10 min; droplet size is monitored by laser diffraction with a Dv90 target of 1–5 µm, and the emulsion is cooled from 30–40°C to 4°C within 2 h to limit antigen interface denaturation. Terminal finished product types are 500 mL polypropylene bottles and, for autogenous game bird use, 100 mL bottles; the bird dose is 0.5 mL subcutaneous. Regulatory oversight for emergency or autogenous avian vaccines is regional; in the European Union, Regulation (EU) 2019/6 and national competent authority approval govern supply, while sterility is verified by Ph. Eur. 2.6.1 and endotoxin by Ph. Eur. 2.6.14 at ≤20 EU/mL. Field experience during emulsification shows that over-shearing beyond 12 min or exceeding 12,000 rpm increases free toxoid in the oil phase and reduces haemagglutination titre, so power-draw limits are written into the batch record. Oral drinking-water premix and granular feed presentations are not used in licensed avian programmes because chlorinated drinking water and feed temperatures above 40°C degrade the toxoid, and no published oral potency model is accepted by regulators.

When Equine Type C Toxoid Formulations Require Reduced Endotoxin Burden

Horses in regions where type C botulism is endemic are occasionally vaccinated with inactivated type C toxoid; published data for licensed equine type C products is more limited than for type B toxoid in the United States. The formulation is a 1 mL intramuscular suspension containing 1.0–1.5 IU type C toxoid and ≤1.25 mg Al³⁺ from aluminium hydroxide. API inclusion is 10–25% v/v after sterile filtration and potency standardisation; single-dose syringes usually omit preservative, while multidose vials contain 0.5% w/v phenol. Benzyl alcohol is generally avoided due to intramuscular irritancy. Downstream production requires depyrogenated Type I glass vials or siliconized prefilled syringes; filling is performed under nitrogen overlay to reduce oxidation of residual phenol. Terminal finished product types are 1 mL single-dose prefilled syringes and 10 mL rubber-stoppered Type I glass vials. Compliance is anchored to Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for endotoxin ≤10 EU/mL, 9 CFR § 113.100 for US export, and EU GMP Annex 2 for biological active substance manufacturing. The main downstream bottleneck is endotoxin burden in the toxoid API; equines show pyrogenic responses at lower endotoxin thresholds than cattle, so depth filtration with 0.2 µm membrane followed by anion-exchange chromatography reduces bulk endotoxin from above 100 EU/mL to below 10 EU/mL. Tablet, capsule, powder, granule, and premix dosage forms are incompatible with the cold-chain and sterility requirements of equine injectable toxoid.

A Lyophilized Intermediate Exists Only Where Multivalent Lines Separate Antigen Storage

In multivalent facility layouts where live viral antigen lines must remain segregated from inactivated toxoid liquids, the type C toxoid API is lyophilised to a powder intermediate. The lyophilization cycle uses a stainless steel tray dryer with freezing ramp of 1°C/min to −45°C, primary drying at −25°C and 0.2 mbar for 36–48 h, and secondary drying at 25°C for 6–8 h; the stabiliser is 2.5% w/v sucrose plus 1.0% w/v mannitol, and residual moisture is controlled below 2.0% w/w by Karl Fischer titration. Published data for this specific configuration is limited; the lyophilized type C toxoid is an intermediate rather than a common licensed final dosage form. Reconstitution at the formulation site uses sterile water for injection at 5–10 mL per gram of powder and is followed by adsorption onto aluminium hydroxide at 4°C for 12–18 h. Formulation addition ratio after reconstitution is adjusted to the same final potency targets as liquid API: 1.0–2.0 IU per cattle dose and 0.5–1.0 IU per bird dose. Terminal finished product types are injectable suspensions in multidose vials after reconstitution and adsorption; tablet, capsule, granule, and direct premix formats are not produced from this intermediate because the lyophilized cake is amorphous and friable, and compression shear plus heat causes unacceptable antigen titre loss. Compliance for the intermediate is governed by Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for endotoxin ≤20 EU/mL, and 21 CFR Part 210/211 for current good manufacturing practice; powder handling after lyophilization takes place in an ISO 14644-1:2015 Class 8 controlled area.